Navigation Links
ARIUS announces first quarter fiscal 2008 financial results
Date:4/11/2008

ended February 29, 2008, the Company's revenue increased to $1,047,294 compared with $108,454 for the same period in fiscal 2007. The increase was primarily the result of the recognition of product and research contract revenue from the Takeda collaboration.

Interest income decreased to $106,792 for the three-month period ended February 29, 2008, compared with $199,923 for the same period in fiscal 2007. The decrease was primarily the result of lower average cash and investment balances.

Research and development costs increased to $2,595,906 for the three-month period ended February 29, 2008, compared to $1,957,328 for the same period in fiscal 2007. The increase was primarily the result of an increase in staffing levels related to an overall increase in activity as the Company is preparing three products for the clinic, accompanied by increased patent and licensing activity.

General and administrative expenses increased to $1,021,281 for the three-month period ended February 29, 2008, compared to $674,336 for the same period in fiscal 2007. The increase was primarily the result of an increase in staffing levels, consulting fees and legal expenses.

As at February 29, 2008, ARIUS' cash and cash equivalents, short-term investments and net working capital position were $9,760,273, $1,299,844 and $8,245,154, respectively, compared with November 30, 2007 balances of $5,635,365, $6,825,190 and $9,088,712, respectively. The Company currently believes that it has adequate financial resources to continue into the fourth quarter of fiscal 2008 based on planned research and development expenditures and operating costs.

About ARIUS

ARIUS is a biotechnology company discovering and developing the next wave of antibody therapeutics. Established in 1999, ARIUS has built a proprietary technology platform, FunctionFIRST(TM), that rapidly identifies and selects antibodies based on their functional ability to affect disease. This antibody gene
'/>"/>

SOURCE ARIUS Research Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Arius Features Preclinical Data on Antibody Candidates at Two Conferences
2. ARIUS Announces Third Quarter Fiscal 2007 Financial Results
3. Arius highlighted at AACR-NCI-EORTC 2007 International Cancer Conference
4. ARIUS to present at Chinese Global Financial Forum
5. ARIUS announces cancer stem cell antibody program successfully completes first toxicology study
6. Arius announces new findings in Trop-2 and CD59 CANCER antibody programs
7. ARIUS to present at BioNorth Biotechnology and Life Sciences Conference
8. ARIUS announces manufacturing agreement with Avid Bioservices for CD44 Cancer Stem Cell antibody
9. ARIUS to Hold Fourth Quarter and Year End 2007 Conference Call
10. Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program
11. ARIUS announces fourth quarter and year-end fiscal 2007 financial results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... 27, 2015 SynGen Inc., a company that ... that harvest stem and progenitor cells from umbilical cord ... today that it has added three new members to ... Blood Business Units focus on product commercialization. ... its Vice President and Chief Financial Officer.  Chuck was ...
(Date:4/27/2015)... tru Shrimp™ Systems announced today that it has ... the exclusive worldwide rights to commercialize Tidal Basin™ technology, ... agreement for the patented technology, developed by world-renowned shrimp ... China, Taiwan, France, Germany, Italy, Spain, the Netherlands and ... from all over the world for our Tidal Basin™ ...
(Date:4/24/2015)... April 24, 2015 Top student social ... San Diego area universities, including UCSD and SDSU, will ... from prominent local, national and nonprofit companies for an ... 5th Annual Social Innovation Challenge 2015 . , ... social venture ideas addressing a diverse range of issues ...
(Date:4/24/2015)... DIEGO , April 24, 2015  Pfenex Inc. ... the development of biosimilar therapeutics including high value and ... its follow-on public offering of 6,000,000 shares of its ... $15.50 per share. Of the shares being offered, 2,610,000 ... shares are being offered by existing stockholders. Pfenex will ...
Breaking Biology Technology:SynGen Inc. Expands Its Management Team 2tru Shrimp™ Systems Acquires Global Patent for Tidal Basin™ Shrimp Production 25th Annual Social Innovation Challenge at University of San Diego - Students Pitch to Live Judging Panel to Take Home $75K 25th Annual Social Innovation Challenge at University of San Diego - Students Pitch to Live Judging Panel to Take Home $75K 3Pfenex Inc. Announces Pricing Of Follow-on Offering 2
... LA JOLLA, Calif., March 18 TorreyPines Therapeutics,Inc. ... initiated a Phase II study of,NGX267, a muscarinic ... to Sjogren,s syndrome., The company is conducting ... square design to evaluate,the safety, tolerability and efficacy ...
... NEOG ) announces the following Webcast:, What: Neogen ... EDT, Where: http://www.videonewswire.com/event.asp?id=46587 , How: ... the address above., ... are unable to participate during the live webcast, the call will,be archived ...
... - Oncolytics Biotech Inc.,(TSX: ONC, NASDAQ: ONCY) ("Oncolytics") ... 7,344,711 entitled "Use of Adenoviruses Mutated in the,VA ... of treating,cancer using adenoviruses that are modified to ... Ras pathway., "This patent expands our adenovirus ...
Cached Biology Technology:TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia 2TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia 3TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia 4Oncolytics Biotech Inc. Announces Issuance of 26th U.S. Patent 2
(Date:4/14/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market, announces that its ... New York Design Awards under the category  ,Product Design ... Design Awards are part of a global multi-disciplinary awards ... from the marketplace, industry and judging panel. Winners will ...
(Date:4/9/2015)... , April 9, 2015 Synaptics Inc. (NASDAQ: ... announced today that it will report financial results for ... 23, 2015, after the close of market. The company ... investors at 2:00 p.m. PT (5:00 p.m. ET), during ... To participate on the live call, analysts and investors ...
(Date:4/2/2015)... Md. , April 2, 2015 At ... Salt Lake City , the American College ... of five new directors to its Board.  Members of ... the ACMG and for forming and advancing its policies ... medical genetics profession. "It,s an eventful time ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3Synaptics to Report Third Quarter Results on April 23 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8
... LEDs may help reduce skin ... in Germany are describing a potential alternative to Botox ... scheduled for the November 5 issue of ACS, ... that high intensity visible light from light emitting diodes ...
... cleavage product, amyloid-b (Ab), builds up into fibrous plaques ... one specialized membrane microdomain to another to be cleaved, ... definitive evidence that Ab plaques are the direct cause ... support this. And working on this hypothesis, scientists are ...
... one step closer to finding a vaccine that better ... at Saint Louis University appears likely to offer significantly ... one in current use. "Not only was it ... better immune response, which suggests it will be more ...
Cached Biology News:American Chemical Society Weekly PressPac Oct. 15, 2008 2American Chemical Society Weekly PressPac Oct. 15, 2008 3American Chemical Society Weekly PressPac Oct. 15, 2008 4American Chemical Society Weekly PressPac Oct. 15, 2008 5American Chemical Society Weekly PressPac Oct. 15, 2008 6American Chemical Society Weekly PressPac Oct. 15, 2008 7American Chemical Society Weekly PressPac Oct. 15, 2008 8Research identifies type of vaccine that holds promise in protecting against TB 2
... on over 20 years of experience in ... Life Sciences, the Freedom EVO platform delivers ... according to future needs. Together with the ... is equipped to successfully operate genomics, proteomics, ...
... Use in any standard fixed-angle ... 16,000 g.,Spin- centrifuge tube filters ... within a centrifuge tube. They filter ... removal, HPLC sample preparation, removal of ...
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. Material: polystyrene ...
12 breakable polypropylene strips of 8 wells each held in a rigid frame. Ideal for antibody assays....
Biology Products: